Compare UVSP & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVSP | INBX |
|---|---|---|
| Founded | 1876 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 983.8M | 999.7M |
| IPO Year | 1994 | 2024 |
| Metric | UVSP | INBX |
|---|---|---|
| Price | $34.93 | $63.64 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 151.5K | ★ 165.8K |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.51% | N/A |
| EPS Growth | ★ 21.32 | N/A |
| EPS | ★ 3.13 | N/A |
| Revenue | ★ $328,056,000.00 | $1,300,000.00 |
| Revenue This Year | $11.65 | N/A |
| Revenue Next Year | $4.77 | N/A |
| P/E Ratio | $11.20 | ★ N/A |
| Revenue Growth | 9.64 | ★ 550.00 |
| 52 Week Low | $24.22 | $10.81 |
| 52 Week High | $36.20 | $94.57 |
| Indicator | UVSP | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 43.11 |
| Support Level | $32.00 | $28.54 |
| Resistance Level | $35.11 | $85.97 |
| Average True Range (ATR) | 0.95 | 4.57 |
| MACD | 0.23 | 0.24 |
| Stochastic Oscillator | 96.01 | 40.45 |
Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.